AU2007247094B2 - Use of flibanserin for the treatment of post-menopausal Sexual Desire Disorders - Google Patents

Use of flibanserin for the treatment of post-menopausal Sexual Desire Disorders

Info

Publication number
AU2007247094B2
AU2007247094B2 AU2007247094A AU2007247094A AU2007247094B2 AU 2007247094 B2 AU2007247094 B2 AU 2007247094B2 AU 2007247094 A AU2007247094 A AU 2007247094A AU 2007247094 A AU2007247094 A AU 2007247094A AU 2007247094 B2 AU2007247094 B2 AU 2007247094B2
Authority
AU
Australia
Prior art keywords
post
menopausal
sexual desire
lifelong
flibanserin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007247094A
Other languages
English (en)
Other versions
AU2007247094A1 (en
Inventor
Stephane Pollentier
Robert Pyke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sprout Pharmaceuticals Inc
Original Assignee
Sprout Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38566195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007247094(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sprout Pharmaceuticals Inc filed Critical Sprout Pharmaceuticals Inc
Publication of AU2007247094A1 publication Critical patent/AU2007247094A1/en
Assigned to SPROUT PHARMACEUTICALS, INC. reassignment SPROUT PHARMACEUTICALS, INC. Request for Assignment Assignors: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Application granted granted Critical
Publication of AU2007247094B2 publication Critical patent/AU2007247094B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2007247094A 2006-05-09 2007-05-07 Use of flibanserin for the treatment of post-menopausal Sexual Desire Disorders Ceased AU2007247094B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74681706P 2006-05-09 2006-05-09
US60/746,817 2006-05-09
US83098706P 2006-07-14 2006-07-14
US60/830,987 2006-07-14
PCT/EP2007/054380 WO2007128802A2 (en) 2006-05-09 2007-05-07 Use of flibanserin for the treatment of post-menopausal sexual desire disorders

Publications (2)

Publication Number Publication Date
AU2007247094A1 AU2007247094A1 (en) 2007-11-15
AU2007247094B2 true AU2007247094B2 (en) 2012-11-01

Family

ID=38566195

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007247094A Ceased AU2007247094B2 (en) 2006-05-09 2007-05-07 Use of flibanserin for the treatment of post-menopausal Sexual Desire Disorders

Country Status (27)

Country Link
US (4) US20070265276A1 (enExample)
EP (1) EP2021006B1 (enExample)
JP (1) JP2009536176A (enExample)
KR (1) KR20090005371A (enExample)
AR (1) AR060880A1 (enExample)
AU (1) AU2007247094B2 (enExample)
BR (1) BRPI0712039A2 (enExample)
CA (1) CA2649938A1 (enExample)
CL (1) CL2007001318A1 (enExample)
DK (1) DK2021006T3 (enExample)
EA (1) EA200802208A1 (enExample)
EC (1) ECSP088874A (enExample)
ES (1) ES2551093T3 (enExample)
HU (1) HUE026156T2 (enExample)
IL (1) IL195135A0 (enExample)
MX (1) MX2008013827A (enExample)
MY (1) MY151048A (enExample)
NO (1) NO20084531L (enExample)
NZ (1) NZ573382A (enExample)
PE (1) PE20080090A1 (enExample)
PL (1) PL2021006T3 (enExample)
PT (1) PT2021006E (enExample)
RS (1) RS54398B1 (enExample)
SI (1) SI2021006T1 (enExample)
TW (1) TW200812586A (enExample)
UY (1) UY30333A1 (enExample)
WO (1) WO2007128802A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785458B2 (en) 2005-08-03 2014-07-22 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US9782403B2 (en) 2001-10-20 2017-10-10 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
CA2599937A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
US20060211685A1 (en) * 2005-03-04 2006-09-21 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
EP1904182A2 (en) * 2005-05-06 2008-04-02 Boehringer Ingelheim International GmbH Method for the treatment of drug abuse with flibanserin
JP2008540672A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 病状に起因する性的機能不全の治療方法
EP1888071A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of drug-induced sexual dysfunction
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
ATE456369T1 (de) 2006-06-30 2010-02-15 Boehringer Ingelheim Int Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
EA200900264A1 (ru) 2006-08-14 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Композиции флибансерина и способ их приготовления
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
JP5220746B2 (ja) * 2006-08-25 2013-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 制御放出システム及びその製造方法
WO2008090742A1 (ja) * 2007-01-23 2008-07-31 National University Corporation Hokkaido University 眼疾患モデル用非ヒト動物
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
USD915009S1 (en) 2018-08-16 2021-03-30 Samsung Electronics Co., Ltd. Clothing care machine
USD1017150S1 (en) 2021-12-28 2024-03-05 Samsung Electronics Co., Ltd. Clothing care machine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035072A1 (en) * 2001-10-20 2003-05-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flibanserin in the treatment of sexual disorders
WO2005007166A1 (en) * 2003-07-16 2005-01-27 Pfizer Limited Treatment of sexual dysfunction

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3406178A (en) * 1964-02-04 1968-10-15 Monsanto Chem Australia Ltd Preparation of 2-substituted benzimidazoles
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US4200641A (en) * 1976-12-21 1980-04-29 Janssen Pharmaceutica, N.V. 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
IT1176613B (it) * 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
HUT43600A (en) * 1985-06-22 1987-11-30 Sandoz Ag Process for production of new thiazole derivatives and medical compound containing those
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US5036088A (en) * 1986-06-09 1991-07-30 Pfizer Inc. Antiallergy and antiinflammatory agents, compositions and use
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
US4954503A (en) * 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
NZ241613A (en) * 1991-02-27 1993-06-25 Janssen Pharmaceutica Nv Highlighting intagliations in tablets
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5225417A (en) * 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
US5492907A (en) * 1992-12-09 1996-02-20 The United States Of America As Represented By The Department Of Health & Human Services Antipsychotic composition and method of treatment
FR2707294B1 (fr) * 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
AU1518595A (en) * 1994-01-14 1995-08-01 Genentech Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
FR2727682A1 (fr) * 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5883094A (en) * 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
US6083947A (en) * 1996-01-29 2000-07-04 The Regents Of The University Of California Method for treating sexual dysfunctions
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
AU731349B2 (en) * 1996-12-02 2001-03-29 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating sexual dysfunctions
SK284690B6 (sk) * 1997-06-11 2005-09-08 The Procter And Gamble Company Ústna dávkovacia forma na zvýšenie ochrany horného tráviaceho traktu
ATE241341T1 (de) * 1997-09-10 2003-06-15 Takeda Chemical Industries Ltd Stabilisierte pharmazeutische zusammensetzung
CH692199A8 (fr) * 1997-10-09 2002-06-14 Cermol S.A. Composes pyridiques et compositions pharmaceutique
JP3724157B2 (ja) * 1997-10-30 2005-12-07 コニカミノルタホールディングス株式会社 映像観察装置
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US20020151543A1 (en) * 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
US6068846A (en) * 1998-08-05 2000-05-30 Melaleuca, Incorporated Methods and materials for treating depression and mood disorder
EP0982030A3 (en) * 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
US6680071B1 (en) * 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
CN1396829A (zh) * 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
US6521623B1 (en) * 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US6586435B2 (en) * 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
EP1414816B1 (en) * 2001-08-02 2005-02-09 BIDACHEM S.p.A. Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US20040132697A1 (en) * 2002-11-06 2004-07-08 Pfizer Inc. Treatment of female sexual dysfunction
WO2004063864A2 (en) * 2003-01-06 2004-07-29 Laura Berman Method and system for computerized sexual function assessment of female users
RU2445095C2 (ru) * 2004-04-22 2012-03-20 Бёрингер Ингельхайм Интернациональ Гмбх Новые фармацевтические композиции для лечения сексуальных расстройств
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20060014757A1 (en) * 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (en) * 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Method for the treatment of attention deficit hyperactivity disorder
CA2599937A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
US20060211685A1 (en) * 2005-03-04 2006-09-21 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
EP1904182A2 (en) * 2005-05-06 2008-04-02 Boehringer Ingelheim International GmbH Method for the treatment of drug abuse with flibanserin
US20060258640A1 (en) * 2005-05-13 2006-11-16 Boehringer Ingelheim International Gmbh Use of Flibanserin in the treatment of chronic pain
JP2008540672A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 病状に起因する性的機能不全の治療方法
EP1888071A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of drug-induced sexual dysfunction
EP1912650B8 (en) * 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
JP2009513604A (ja) * 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
CA2641917A1 (en) * 2006-02-18 2007-08-23 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
US20090176698A1 (en) * 2006-02-20 2009-07-09 Boehringer Ingelheim International Gmbh Benzimidazolone Derivatives for the Treatment of Urinary Incontinence
US20090247546A1 (en) * 2006-02-28 2009-10-01 Boehringer Ingelheim International Gmbh Treatment of Prevention of Valvular Heart Disease with Flibanserin
ATE456369T1 (de) * 2006-06-30 2010-02-15 Boehringer Ingelheim Int Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
US20090239881A1 (en) * 2006-07-14 2009-09-24 Boehringer Ingelheim International Gmbh Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900264A1 (ru) * 2006-08-14 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Композиции флибансерина и способ их приготовления
JP5220746B2 (ja) * 2006-08-25 2013-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 制御放出システム及びその製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035072A1 (en) * 2001-10-20 2003-05-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flibanserin in the treatment of sexual disorders
WO2005007166A1 (en) * 2003-07-16 2005-01-27 Pfizer Limited Treatment of sexual dysfunction

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9782403B2 (en) 2001-10-20 2017-10-10 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US11058683B2 (en) 2001-10-20 2021-07-13 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US8785458B2 (en) 2005-08-03 2014-07-22 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US9730927B2 (en) 2005-08-03 2017-08-15 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US10335407B2 (en) 2005-08-03 2019-07-02 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US10874668B2 (en) 2005-08-03 2020-12-29 Sprout Pharmaceuticals, Inc. Use of Flibanserin in the treatment of obesity

Also Published As

Publication number Publication date
UY30333A1 (es) 2008-01-02
DK2021006T3 (en) 2015-11-23
WO2007128802A2 (en) 2007-11-15
BRPI0712039A2 (pt) 2011-12-20
PE20080090A1 (es) 2008-03-14
PT2021006E (pt) 2015-11-12
PL2021006T3 (pl) 2015-12-31
EA200802208A1 (ru) 2009-04-28
NZ573382A (en) 2012-02-24
NO20084531L (no) 2008-12-02
WO2007128802A3 (en) 2008-06-12
AU2007247094A1 (en) 2007-11-15
CA2649938A1 (en) 2007-11-15
RS54398B1 (sr) 2016-04-28
MX2008013827A (es) 2008-11-10
US20070265276A1 (en) 2007-11-15
ES2551093T3 (es) 2015-11-16
JP2009536176A (ja) 2009-10-08
TW200812586A (en) 2008-03-16
MY151048A (en) 2014-03-31
HUE026156T2 (en) 2016-06-28
EP2021006B1 (en) 2015-08-12
ECSP088874A (es) 2008-12-30
SI2021006T1 (sl) 2016-01-29
US20130190326A1 (en) 2013-07-25
US20150374683A1 (en) 2015-12-31
CL2007001318A1 (es) 2008-01-18
KR20090005371A (ko) 2009-01-13
AR060880A1 (es) 2008-07-16
US20150051221A1 (en) 2015-02-19
IL195135A0 (en) 2009-09-22
EP2021006A2 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
AU2007247094B2 (en) Use of flibanserin for the treatment of post-menopausal Sexual Desire Disorders
US10307420B2 (en) Treating sexual desire disorders with flibanserin
AU2006311038B2 (en) Use of flibanserin for the treatment of pre-menopausal Sexual Desire Disorders
EP1740180B1 (en) Use of flibanserin in the treatment of premenstrual disorders
AU2002333894A1 (en) Use of flibanserin in the treatment of sexual disorders
WO2007048801A2 (en) Sexual desire enhancing medicaments comprising benzimidazolone derivatives
EP1955699A1 (en) Use of flibanserin for the treatment of insomnia
US20190262336A1 (en) Treating sexual desire disorders with flibanserin

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SPROUT PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): BOEHRINGER INGELHEIM INTERNATIONAL GMBH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired